Science Explorer Back to mapMap
Discussion
Company · Baton Rouge · United States

TumorEnd (United States)

tumorend.comROR OpenAlex
Research works
4
▲ 203% vs 2018-21
Citations
44
11.0 per fractional work
Top-10% rate
10.0%
all institutions 10.0%
Open access
83%
world 40%
International
44%
world 18%
TumorEnd (United States)

Not ranked overall: TumorEnd (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does TumorEnd (United States) work in?

In all years, 40% of research at TumorEnd (United States) is in Health Sciences, 38% in Life Sciences. Its largest fields are Medicine (40%), Biochemistry, Genetics and Molecular Biology (30%), Chemistry (22%).

Health Sciences: 2 fractional works · 40.0% of its workMedicine: 2 fractional works · 40.0% of its workLife Sciences: 2 fractional works · 37.5% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 30.0% of its workImmunology and Microbiology: 0 fractional works · 7.5% of its workPhysical Sciences: 1 fractional works · 22.5% of its workChemistry: 1 fractional works · 22.5% of its workALL ITS WORKTumorEnd (UnitedStates)4fractional works, all years
Life Sciences38%Physical Sciences22%Health Sciences40%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 4 fields, with their numbers
    1. Medicine240.0%
    1. Biochemistry, Genetics and Molecular Biology130.0%
    2. Immunology and Microbiology07.5%
    1. Chemistry122.5%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from TumorEnd (United States)?

The most cited paper from TumorEnd (United States) is "Thioglycosides Are Efficient Metabolic Decoys of Glycosylation that Reduce Selectin Dependent Leukocyte Adhesion" (Shuen-Shiuan Wang, Xuefeng Gao, Virginia del Solar et al., 2018), with 38 citations. Next come "A systematic analysis of acceptor specificity and reaction kinetics of five human α(2,3)sialyltransferases: Product inhibition studies illustrate reaction mechanism for ST3Gal-I" (32) and "Overexpression of α2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis" (29).

Most cited papers
#PaperReleasedCitations
1 Thioglycosides Are Efficient Metabolic Decoys of Glycosylation that Reduce Selectin Dependent Leukocyte Adhesion Shuen-Shiuan Wang, Xuefeng Gao, Virginia del Solar et al. · Cell chemical biology Open access 18 Oct 2018 38
2 A systematic analysis of acceptor specificity and reaction kinetics of five human α(2,3)sialyltransferases: Product inhibition studies illustrate reaction mechanism for ST3Gal-I Rohitesh Gupta, Khushi Lall Matta, Sriram Neelamegham · Biochemical and Biophysical Research Communications Open access 17 Dec 2015 32
3 Overexpression of α2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis Shilpa A. Patil, Wiam Bshara, Carl Morrison et al. · Glycoconjugate Journal Open access 20 Aug 2014 29
4 Identification and Biochemical Characterization of the Novel α2,3-Sialyltransferase WbwA from Pathogenic Escherichia coli Serotype O104 Diana Czuchry, Paul Desormeaux, Melissa A. Stuart et al. · Journal of Bacteriology Open access 22 Sep 2015 17
5 Acceptor specificities and selective inhibition of recombinant human Gal- and GlcNAc-transferases that synthesize core structures 1, 2, 3 and 4 of O-glycans Yin Han Gao, Rajindra P. Aryal, Tongzhong Ju et al. · Biochimica et Biophysica Acta (BBA) - General Subjects Open access 8 Apr 2013 17
All 8 most cited papers, with filters and sorting

Which research topics does TumorEnd (United States) publish most on?

By volume in 2022-now: Management of metastatic bone disease, Sarcoma Diagnosis and Treatment, Musculoskeletal synovial abnormalities and treatments and Bone Tumor Diagnosis and Treatments.

Management of metastatic…0Management of metastatic bone disease: 0 fractional worksSarcoma Diagnosis and Tr…0Sarcoma Diagnosis and Treatment: 0 fractional worksMusculoskeletal synovial abnormalities and treatments: 0 fractional worksBone Tumor Diagnosis and Treatments: 0 fractional works
SurgeryPulmonary and Respiratory MedicineRheumatology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Management of metastatic bone disease Surgery 0 works
  2. 2 Sarcoma Diagnosis and Treatment Pulmonary and Respiratory Medicine 0 works
  3. 3 Musculoskeletal synovial abnormalities and treatments Rheumatology 0 works
  4. 4 Bone Tumor Diagnosis and Treatments Rheumatology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available82.7%not open17.3%

World: 40% of research is openly available.

with international co-authors44.1%domestic only55.9%

World: 18% is written across borders.

How has TumorEnd (United States)'s research output changed?

Output in 2022-2025 was 203% higher than in 2018-2021.

201020152020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Baton Rouge

All research institutions in Baton Rouge

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about TumorEnd (United States). Posts are plain text and can be reported.